Guggenheim Securities, LLC has issued a statement on behalf of former Pfizer Chief Executive Officer Ian Read and former Chief Financial Officer Frank D'Amelio. The decision has been made not to participate in Starboard Value's efforts regarding Pfizer. Full support is given to Pfizer Chairman and CEO Albert Bourla, the senior management team, and the board, with confidence that they will deliver shareholder value over time.
Recently, the Wall Street Journal reported that activist investor Starboard Value took a roughly $1 billion stake in Pfizer and is advocating for substantial changes to enhance the company's lackluster performance.
While the specifics of Starboard's plans remain unclear, the firm has reached out to Ian Read and Frank D'Amelio, both of whom have previously expressed interest in supporting Starboard's turnaround initiatives, according to the Journal.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.